Using t-test. Changes over time were analyzed using repeated measures analysis > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Using t-test. Changes over time were analyzed using repeated measures analysis of variance. P < 0.05 in the 2-tailed test was regarded as significant. Results are expressed as means ?SEM.Prothrombin fragment F1+nmol/l 0,5 0,4 * *Results Baseline characteristics of the study patients showed minor differences in smoking and familial predisposition (Table 1).FVIIa and thrombin generation0,0,0,0 admission after 3 daysThrombin generation in vivo, assessed by concentrations of prothrombin fragment F1 + 2, increased significantly after 3 days (p < 0.01, Figure 1). This effect was noticed both in the Epo group and the placebo group without any significant difference between the two groups. Measurement of FVII showed elevated total FVII after Epo as compared to the 3-Amino-1H-indazole-4-carbonitrile placebo group, yet active FVII remained similar between the groups (Table 2).Blood countPlaceboEpo* p < 0.Figure 1 Epo does not alter thrombin generation. Prothrombin fragment F1 + 2 of patients treated with Epo or placebo on admission and after 60 hours. Values are expressed as mean + SEM. *p < 0.01 compared to the values on admission.On admission haemoglobin (Epo 14.8 ?0.3 mg/dl, placebo 14,3 ?0.2 mg/dl), haematocrit (Epo 43 ?0.5 , placebo 42 ?0.5 )and platelet count (Epo 215 ?56 ?109/l, placebo 224 ?71 ?109/l) were comparable in both groups (n = 45). Similarly haemoglobin, haematocrit and platelet count were comparable in the subgroup with the platelet activation study (n = 45). After 5 days, the maximal platelet count was elevated in the Epo group (265 ?70 ?109/l) as compared to the placebo group (232 ?74 ?109/l, p = 0.011, Figure 2, n = 94). In contrast, haemoglobin levels did not differ between the two groups after 5 days (Epo 14.8 ?1.6 versus placebo 15 ?1.3 mg/dl, p = 0.593, Figure 2).Platelet reactivityTable 1 Baseline characteristics of the platelet study patientsCharacteritics Age (years) Women Men Diabetes Current smoker Arterial hypertension Hypercholesterinemia Fam. Predisposition Epoetin- (n = 23) 61.9 ?2.5 6 (26) 17 (74) 4 (17) 7 (30) 14 (61) 11 (48) 10 (43) Placebo (n = 22) 61.3 ?13.9 7 (32) 15 (68) 3 (14) 11 (50) 13 (59) 13 (59) 4 (18)After PCI, platelet aggregation decreased significantly as expected in response to periinterventional therapy with clopidogrel and aspirin (Figure 3A-E). This effect was most distinctive after 12 (TRAP- and collagen-induced, Figure 2C and E) hours and2 days (unstimulated cells and after stimulation with ADP and ASPI, Figure 2A,B and D), respectively. However, there was no significant difference between the Epo and the placebo group. After 3 and 5 days, platelet aggregation increased gradually but did not yet PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/10714611 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/13485127 reach initial levels except for TRAPstimulated platelets. Similarly, no statistically significant differences were observed in circulating platelet activation markers TG and P-selectin before and after 3 days in the Epo group as compared to the placebo group (Table 2).Data are presented as n ( ) or mean ?SEM.Discussion Major findings of our study are as follows: (1) Although total FVII was elevated after treatment with Epo, no difference in the increase in active FVII and thrombin generation was observed between 3-Nitro-6-(trifluoromethyl)pyridin-2(1H)-one the two groups. (2) After treatment with Epo in patients with AMI and successful primary percutaneous coronary intervention the number of circulating platelets increased. (3) However, platelet activation was not altered after Epo as compared to the patients receiving placebo. Platelets play a central role in the haemostatic.